Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 January 2018 Photo Charl Devenish
ISG’s Sarah Frank researches impact of historic conflicts on society
Dr Sarah Frank, postdoctoral researcher at the ISG.

History has an interesting connection with society, as we all grow up learning about our country’s history and studying it at school. However, what we learn at school is often a glorified version of events. It can sometimes be challenging for historians to come to grips with the most accurate version of a particular ‘history’. 

Dr Sarah Frank is a postdoctoral research fellow with the International Studies Group (ISG), who fell in love with history at a young age. She says, "I was very lucky to have outstanding history teachers at school who fostered my interest and curiosity." Early on, though, she experienced disappointment. "In school, there was a series of biographies of American leaders and presidents written for children. I remember feeling betrayed when I subsequently learnt that the biographies had not presented a well-balanced narrative. That is when I learnt that history could be debated and interpreted—and it is full of nuances."

Interested in conflict shaping lives

Dr Frank was particularly intrigued by the social and political history of the Second World War (WWII). She describes her interest in this way: "The Second World War looms in popular memory as much as in the historical one. I am interested in how conflict shaped people’s lives during and after the war." Being a speaker of French helped her to focus on the impact of the war on France, and having spent a few years living in West Africa, confronted with the lingering colonial past, she decided to home in on the French empire, with particular attention to colonies, captivity, and the repercussions of war experiences when soldiers returned home. Additionally, she explores the themes of decolonisation, the roots of independence movements, and the lingering ties between the former imperial powers and former colonies.

Although she grew up near Boston, Massachusetts, studied for her master's in Dublin, and has lived in far-flung places such as Guinea (while serving with the Peace Corps) and Dakar, Dr Frank says, "I have lived in a lot of places, but Bloemfontein is definitely one of my favourites!"

“I was very lucky to have outstanding
history teachers at school who
fostered my interest and curiosity.”
Dr Sarah Frank

Colonial POWs her new focus

Currently, Dr Frank is writing a book based on her PhD research, which delved into the experiences of approximately 85 000 soldiers in captivity from across the French Empire, who fought in France from 1939-1940. The Germans decided to racially separate the colonial prisoners of war (CPOWs), taking white prisoners to Germany and leaving the colonial prisoners in camps across occupied France. This created opportunities for colonial prisoners to interact with the French civilians, something which rarely occurred in the strict hierarchical colonial regime. Perhaps surprisingly, considering the racism of both the French and German regimes, Colonial prisoners fared better in captivity in France than their French counterparts did in Germany.

Dr Frank's next project will trace the return of the African soldiers who fought during the Second World War. She seeks to understand what happened to them as well as their families when they returned, and to see if their experience actually impacted the growing independence movements which arose following 
WWII.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept